EUCTR2021-004003-41-ES进行中（未招募）1 期
A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnant girls from 9 to 17 years of age, and in non-pregnant adult women from 18 to 49 years of age. - RSV MAT-039
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Healthy Non-pregnant Adult Women from 18-49 YOA
- •Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study-specific procedure.
- •A healthy female participant, as established by medical history and clinical examination, between and including 18 to 49 YOA at the time of the first study intervention administration.
- •Body mass index (based on participant’s report) 17.0 to 39.9 kg/m^2, inclusive for adult participants.
- •Female participants of childbearing potential may be enrolled in the study, if the participant:
- •- has practiced adequate contraception for 1 month prior to study intervention administration, and
- •- has a negative pregnancy test on the day of study intervention administration, and
- •- has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administrations.
- •Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
- •Healthy non-pregnant Girls from 9-17 YOA
- •Participants and participants’ parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Written or witnessed/thumb printed informed consent obtained from the participant*/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
- •-*Written informed consent obtained from parents/LARs and written informed assent obtained from the participant if she is less than legal age. The legal age is determined according to local regulations in each participating country.
- •-In case the legal age is achieved during the conduct of the study, an additional written informed consent from the participant should be obtained at the time of the legal age.
- •A healthy female participant between and including 9 and 17 YOA at the time of the first study intervention administration.
- •-Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.
- •Body mass index by age between 5 percentile and 95 percentile (inclusive) for pediatric participants.
- •Female participants of childbearing potential may be enrolled in the study, if the participant:
- •-has a negative pregnancy test on the day of study intervention administration, and is abstinent during the entire treatment period and for 1 month before and after completion of the study intervention administration series (and if so, this is to be documented in the source documents at each vaccination visit)
- •-or has practiced adequate contraception for 1 month prior to study intervention administration and has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 126
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 126
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical conditions
- •Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Current autoimmune disorder (based on medical history and physical examination;), for which the participant has received immune-modifying therapy within 6 months, before study vaccination.
- •Hypersensitivity to latex.
- •Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions, as determined by physical examination or medical history that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- •Significant or uncontrolled psychiatric illness.
- •Documented human immunodeficiency virus (HIV)-positive participant.
- •Any clinically significant* hematological parameter and/or biochemical laboratory abnormality from the test requested by the investigator based on medical judgment prior to enrolment
- •-*The investigator should use his/her clinical judgment to decide whether the test is needed, and which abnormalities are clinically significant. If he/she decides to run this test, the investigator will need to review the test results before proceeding with the administration of the study vaccine.
- •Lymphoproliferative disorder or malignancy within 5 years before study vaccination (excluding effectively treated non-melanoma skin cancer).
- •Prior/Concomitant therapy
- •Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before the first doses (Day -29 to Day 1), or their planned use during the study period.
- •Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s)* administration with the exception of any licensed influenza vaccine which may be administered = 15 days before or after study vaccinations (dTpa and RSV maternal vaccines).
- •-*In case emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine (if it is used according to the local governmental recommendations and that the Sponsor is notified accordingly). Therefore, COVID-19 vaccines will be allowed, when administered = 15 days before or after study vaccinations (dTpa and RSV maternal vaccines).
- •Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
- •Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period.
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) to 2 months after first vaccination. For corticosteroid
研究者
相似试验
进行中（未招募）
1 期
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysisTreatment of anemia due to chronic kidney disease in patients not yet on hemodialysisMedDRA version: 15.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857EUCTR2011-005058-70-SKAPOTEX Inc.196
进行中（未招募）
不适用
Study of safety, efficacy, pharmacokinetics and pharmacodynamics of APO-EPO versus Epogen®/Procrit® in patients with anemia and chronic kidney disease not yet on hemodialysisEUCTR2011-005058-70-HUAPOTEX Inc.196
进行中（未招募）
不适用
Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP-T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP-T or Infanrix hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican InfantsPrevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, prevention against invasive infections caused by Haemophilus influenzae type b and infection caused by hepatitis B virusMedDRA version: 14.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-004456-19-Outside-EU/EEASanofi Pasteur S.A1,190
进行中（未招募）
1 期
Open label trial to compare BI 207127 to Telaprevir in HCV patientsMedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsHepatitis CEUCTR2012-004544-30-DKBoehringer Ingelheim270
进行中（未招募）
不适用
Open label trial to compare BI 207127 to Telaprevir in HCV patientsHepatitis CEUCTR2012-004544-30-SEBoehringer Ingelheim AB270